Could weight-loss drugs eat the world?
Scientists are finding that anti-obesity medicines can also help many other diseases
Source: livemint.com
📰 Waheed Jamal News
Waheed Jamal News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Waheed Jamal. Real-time updates on events, politics, business and more.
Could weight-loss drugs eat the world?
Scientists are finding that anti-obesity medicines can also help treat dozens of other diseases | Science & technology
Source: economist.com
Lilly, Boehringer say Jardiance slows kidney disease progression in trial
FRANKFURT (Reuters) - Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the progression of chronic kidney diseas...
Source: wkzo.com
Empagliflozin trial halted after successful outcome in CKD
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Richard Haynes William Herrington Waheed Jamal Boehringer Ingelheim Eli Lilly Clinician Scientist Oxford Population Health University Of Oxford
Source: europeanpharmaceuticalreview.com
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Empagliflozin benefits adults hospitalised for acute heart failure
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
Source: europeanpharmaceuticalreview.com
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1
Source: businesswireindia.com
Boehringer Ingelheim: CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 If
Source: finanznachrichten.de
Boehringer Ingelheim: Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
In a new sub-analysis of the landmark EMPEROR-Preserved Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney
Source: finanznachrichten.de
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined relative risk versus placebo of...
Source: newswire.ca